Patent intelligence · US
US 11344605
Therapeutic use of inhibitors of t cell activation or stimulation
Therapeutic use of inhibitors of t cell activation or stimulation
Patent details — US 11344605
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 31, 2022
- Expiration
- May 26, 2042
- Applicant
- HUMANITAS MIRASOLE S.P.A.
- Claims
- 17
- CPC classes
- A61K, A61K38/1709, A61K38/1774, A61K39/001102
Quick answer
US 11344605 (Therapeutic use of inhibitors of t cell activation or stimulation) is held by HUMANITAS MIRASOLE S.P.A.. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HUMANITAS MIRASOLE S.P.A.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K38/1709, A61K38/1774, A61K39/001102, A61K48/00, A61P
More from HUMANITAS MIRASOLE S.P.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 11344605?
US 11344605 (Therapeutic use of inhibitors of t cell activation or stimulation) is held by HUMANITAS MIRASOLE S.P.A.. Status: granted. Granted May 31, 2022. Expires May 26, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11344605?
HUMANITAS MIRASOLE S.P.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 11344605 expire?
Our index shows an expiration date of May 26, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.